CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 42 enrolled
Drug / intervention
MP-214drug
Likely dose
MP-214 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01626885
NCT01626885Phase 3Completed
CompareCT.gov

A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia

Tanabe Pharma Corporation·interventional·Posted Jun 25, 2012·Updated Jan 6, 2026

In Brief

A Phase 3 clinical trial evaluating MP-214 for Schizophrenia. Completed, enrolled 42 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2012
Enrollment StartMay 1, 2012
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 14.0 years ago

Interventions

MP-214drug

Patients who meet eligibility criteria will be administered a once daily oral fixed dose (3mg) of MP-214 for four weeks, then flexible dose (1.5-9 mg) of MP-214